TPMT/NUDT15 pharmacogenetic testing now commissioned

TPMT and NUDT15 pharmacogenetic testing is now commissioned on the NHS for both adult and paediatric patients with Acute Lymphoblastic Leukaemia only, the updated  national genomic test directory can be found here

These pharmacogenetic tests will identify if a patient is susceptible to an increased risk of myelosuppression when treated with thiopurines, such as 6-mercaptopurine (6MP).

For adult patients the dosing guidelines can be found here. It is important to note that these guidelines give dosing recommendations for 6MP for patients aged 25 years or older only and consider only the most common TPMT/NUDT15 variants. The recommendations in the guidelines are not intended to guide the treatment of patients under 25 years, or patients enrolled in a research study and in such circumstances, clinical staff should consult the research study treatment protocol or the locally agreed treatment protocol.

If you have any questions, please contact [email protected] and [email protected] OR please contact the authors of the guidelines.